Literature DB >> 15688276

Lessons from failure--preparing for future HIV-1 vaccine efficacy trials.

Barney S Graham, John R Mascola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15688276     DOI： 10.1086/428406

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  21 in total

1.  HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Authors:  Nicole A Doria-Rose
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

2.  Augmented designs to assess immune response in vaccine trials.

Authors:  Dean Follmann
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

3.  Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.

Authors:  Surender Khurana; James Needham; Susan Park; Bonnie Mathieson; Michael P Busch; George Nemo; Phillipe Nyambi; Susan Zolla-Pazner; Suman Laal; Joseph Mulenga; Elwyn Chomba; Eric Hunter; Susan Allen; James McIntyre; Indira Hewlett; Sherwin Lee; Shixing Tang; Elliot Cowan; Chris Beyrer; Marcus Altfeld; Xu G Yu; Anatole Tounkara; Ousmane Koita; Anatoli Kamali; Nga Nguyen; Barney S Graham; Deborah Todd; Peter Mugenyi; Omu Anzala; Eduard Sanders; Nzeera Ketter; Patricia Fast; Hana Golding
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

Review 4.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

Review 5.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

6.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

7.  Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Authors:  Richard A Koup; Mario Roederer; Laurie Lamoreaux; Jennifer Fischer; Laura Novik; Martha C Nason; Brenda D Larkin; Mary E Enama; Julie E Ledgerwood; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

Review 8.  HIV-1 neutralizing antibodies: understanding nature's pathways.

Authors:  John R Mascola; Barton F Haynes
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial.

Authors:  Marcos Pérez-Losada; David Posada; Miguel Arenas; David V Jobes; Faruk Sinangil; Phillip W Berman; Keith A Crandall
Journal:  Retrovirology       Date:  2009-07-15       Impact factor: 4.602

10.  A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.

Authors:  Hanna C Kelker; Vincenza R Itri; Fred T Valentine
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.